Harvard Bioscience (HBIO) Free Cash Flow (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Free Cash Flow data on file, last reported at -$1.1 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 144.0% year-over-year to -$1.1 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a 273.78% increase from a year earlier, with the FY2025 full-year figure at $5.5 million, up 554.4% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$1.1 million, down from -$545000.0 in the prior quarter.
• Over the last five years, Free Cash Flow for HBIO reached as high as $4.1 million in Q3 2023 and fell as low as -$2.5 million in Q1 2022.
• Historically, Free Cash Flow has averaged $881235.3 across 5 years, with a median of $877000.0 in 2025.
• Across the five-year window, Free Cash Flow slumped 377.31% in 2022 and jumped 1901.93% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at $2.4 million in 2022, then soared by 42.1% to $3.5 million in 2023, then plunged by 59.0% to $1.4 million in 2024, then slumped by 138.27% to -$545000.0 in 2025, then tumbled by 99.63% to -$1.1 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$1.1 million in Q1 2026, -$545000.0 in Q4 2025, and $877000.0 in Q3 2025.